Fourth Quarter and Year-end 2012 earnings season is past now form Ligand Pharma as well as big pharma/biotech players. I assembled the latest (and historical) sales and royalty information for LGND's key product PROMACTA (eltrombopag) and it's sole competitive, NPLATE from Amgen AMGN.
(continue reading the full post for the figures and commentary)
(continue reading the full post for the figures and commentary)
And here are the comments from Merck's 4q-2012 earnings call:
"So that’s the first one, in terms of generally new launches, as I said repeatedly we’ve had lots of new launches, but they have generally being niche specialty products. Actually as you rightly say, they now account for about 7% of total, so given that there is no single big product in there almost several big products in there not bad. So what are the lesions we are seeing?
First of all we are seeing great performances in short, if you look at things like for Promacta in the U.S.
As you will also see, our U.S. business is stabilizing, right. So it’s stop rolling and it’s beginning to look a bit more encouraging in terms of its overall performance. And I think all of that together the performance of Promacta, Votrient and other newer products, also I think reflect nothing lost in terms of the sales force changes at all." (via SeekingAlpha)
"So that’s the first one, in terms of generally new launches, as I said repeatedly we’ve had lots of new launches, but they have generally being niche specialty products. Actually as you rightly say, they now account for about 7% of total, so given that there is no single big product in there almost several big products in there not bad. So what are the lesions we are seeing?
First of all we are seeing great performances in short, if you look at things like for Promacta in the U.S.
As you will also see, our U.S. business is stabilizing, right. So it’s stop rolling and it’s beginning to look a bit more encouraging in terms of its overall performance. And I think all of that together the performance of Promacta, Votrient and other newer products, also I think reflect nothing lost in terms of the sales force changes at all." (via SeekingAlpha)
RSS Feed
